3.8 Review

Bone health and hormonal contraception

Journal

MINERVA OBSTETRICS AND GYNECOLOGY
Volume 73, Issue 6, Pages 678-696

Publisher

EDIZIONI MINERVA MEDICA
DOI: 10.23736/S2724-606X.20.04688-2

Keywords

Bone density; Contraceptive agents, hormonal; Menopause; Osteoporosis

Ask authors/readers for more resources

Short-term and long-term steroid contraceptive systems may have negative effects on bone health in adolescent girls, but seem to have minimal impact on bone health in perimenopausal women. Depot medroxyprogesterone acetate (DMPA) may lead to bone loss with prolonged use, while other progestin-based contraceptives do not have detrimental effects on bone health. Further randomized studies are needed for confirmation.
INTRODUCTION: Short-term and long-term steroid contraceptive systems are widely employed in adolescents and premenopausal women; they could induce variation in bone metabolism, but whether these changes increase the overall fracture risk is not yet clear. EVIDENCE ACQUISITION: A systematic search of scientific publications about hormonal contraceptives and bone metabolism in reproductive age women was conducted. EVIDENCE SYNTHESIS: In adolescent girl, combined oral contraceptives could have a deleterious effect on bone health when their onset is within three years after menarche and when they contain ethinyl estradiol at the dose of 20 mcg. In perimenopausal women, steroid contraceptives seem not influence bone health nor increase osteoporotic fractures risk in menopause. The oral progestogens intake is not related to negative effects on skeletal health. Depot medroxyprogesterone acetate (DMPA) induce a prolonged hypoestrogenism with secondary detrimental effect on healthy bone; the higher bone loss was observed at the DMPA dose of 150 mg intramuscular such as after long-term DMPA-users. Progestin-based implants and intrauterine devices have not negative effect on bone health. CONCLUSIONS: Since sex-steroid drugs induce variations in hormonal circulating concentrations, they may negatively affect bone metabolism. Contraceptive choice should be tailored evaluating any possible effect on bone health. Clinicians should always perform a precontraceptive counselling to identify any coexisting condition that may affect bone health. Further randomized studies are needed to confirm these results.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available